Lyell Immunopharma Inc. (LYEL) Is A Stock You Should Watch

As of Friday close, Lyell Immunopharma Inc.’s (NASDAQ:LYEL) stock was up $0.62, moving up 9.32 percent to $7.27. The average number of shares traded per day over the past five days has been 952,020 shares. 5 times new highs have been achieved over the past 5 days, with a $1.70 gain in that time frame. In the last twenty days, the average volume was 634,560, while in the previous 50 days, it was 923,944.

Since last month, LYEL stock rose 6.75%. Shares of the company fell to $5.12 on 07/12/22, the lowest level in the past month. A 52-week high of $19.84 was reached on 01/04/22 after having rallying from a 52-week low of $3.57. Since the beginning of this year, LYEL’s stock price has dropped by -6.07% or -$0.47, and marked a new high 2 times. However, the stock has declined by -63.36% since its 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Financial Health

In the three months ended March 30, Lyell Immunopharma Inc.’s quick ratio stood at 15.20, while its current ratio was 15.20, showing that the company is able to pay off its debt. Based on annual data, LYEL earned $225.43 million in gross profit and brought in $10.65 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -27.00%. Return on equity (ROE) for the past 12 months was -27.60%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. LYEL’s revenue rose 100.0% to -$5.38 million during the quarter, while net income inched up to $0.55 million. While analysts expected Lyell Immunopharma Inc. to report -$0.29 quarterly earnings, the actual figure was -$0.28 per share, beating the consensus estimate by 3.40%. During the quarter, the company generated -$32.86 million in EBITDA. The liabilities of Lyell Immunopharma Inc. were 153.63 million at the end of its most recent quarter ended March 30, and its total debt was $68.81 million. The value of shareholders’ equity is $247.82 million.

Technical Picture

This quick technical analysis looks at Lyell Immunopharma Inc.’s (LYEL) price momentum. With a historical volatility rate of 62.54%, the RSI 9-day stood at 77.67% on 05 August.

With respect to its five-day moving average, the current Lyell Immunopharma Inc. price is up by +30.52% percent or $1.70. At present, LYEL shares trade +8.18% above its 20-day simple moving average and +29.36% percent above its 100-day simple moving average. However, the stock is currently trading approximately +73.10% above its SMA50 and -47.77% below its SMA200.

Stochastic coefficient K was 87.70% and Stochastic coefficient D was 75.42%, while ATR was 0.59. Given the Stochastic reading of 85.71% for the 14-day period, the RSI (14) reading has been calculated as 69.56%. As of today, the MACD Oscillator reading stands at 0.68, while the 14-day reading stands at 0.75.

Analyst Ratings

Morgan Stanley launched its rating on Lyell Immunopharma Inc. (NASDAQ: LYEL) to an Overweight in a note to investors on July 12, 2021. Lyell Immunopharma Inc. (LYEL) has been rated Buy by analysts. According to 0 brokerage firms, LYEL is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Lyell Immunopharma Inc. stock as buy, with 3 recommending it as overweight.

With a median target price of $15.00, the current consensus forecast for the stock is $13.00 – $15.00. Based on these forecasts, analysts predict Lyell Immunopharma Inc. (LYEL) will achieve an average price target of $14.33.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]